Background: Endothelin contributes to the maintenance of vascular tonus in both the systemic circulation and in regional vascular beds. The purpose of the study was to measure the effect of the endothelin A antagonist BQ-123 on renal hemodynamics, tubular function, vasoactive hormones, and blood pressure (BP) in healthy men.
E
ndothelins (ETs) are amino acid peptides. They are produced by the cardiovascular system and exert their effect through at least two types of receptors (ie, ET A and ET B receptors). The ET A receptor is highly expressed in vascular smooth muscle cells and seems to be an important receptor in mediating vasoconstriction. The ET B receptor is expressed both in vascular smooth muscle cells mediating vasoconstriction, and on endothelial cells where stimulation results in vasodilatation due to production of nitric oxide. Many studies have indicated that endothelins are involved in cardiovascular homeostasis in healthy men, 1 and in many diseases such as heart failure, 2 pulmonary hypertension, 3 renal failure, 4 and arterial hypertension 5, 6 due to their direct effect on vascular tone and their contribution to vascular remodeling by enhancing proliferation of smooth muscle cells. However, a recent large study has questioned the importance of endothelin in heart failure. 7 The effect of ET antagonists on renal sodium handling and vasoactive hormones, especially the renin-angiotensin system and the natriuretic peptide system is not clarified. It is our hypothesis that ET A antagonism promotes renal sodium excretion despite a possible stimulation of vasoconstrictor and sodium-retaining hormones.
The purpose of the present study was to measure the effect of the ET A antagonist BQ-123 on renal plasma flow (RPF), glomerular filtration rate (GFR), fractional excretion of sodium (FE Na ), and lithium clearance (C Li ), plasma concentrations of renin (PRC), angiotensin II (Ang II), aldosteron (Aldo), vasopressin (AVP), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and blood pressure (BP). A randomized, placebo-controlled, double-blind dose-response study was done in healthy subjects using three different doses of BQ-123 in addition to placebo.
Methods

Study Subjects
Healthy subjects were included in the study. The inclusion criteria were aged 18 to 40 years, and both men and women. The exclusion criteria were: history or clinical signs of disease in the heart, lungs, liver, kidneys, brain, or endocrine organs; arterial hypertension; diabetes mellitus; neoplastic disease; daily use of medicine; alcohol abuse (defined as more than 21 drinks a week for men and more than 14 drinks a week for women); abnormal laboratory screening including B-hemoglobin and B-white cell count, plasma creatinine, aspartate aminotransferase, albumin, sodium, potassium, and urinary albumin, glucose, and hemoglobin; an abnormal electrocardiogram; pregnancy or risk of pregnancy; blood donation less than 1 month before the study; body mass index Ͼ30 kg/m 2 ; and unwillingness to participate in the study. The withdrawal criteria were development of one of the exclusion criteria, side effects of the test drug, and withdrawal of the acceptance to participate.
Design
The study was a double-blinded, placebo-controlled crossover study. All subjects received infusion of placebo and three different doses of BQ-123 on 4 different days with an interval of at least 14 days corresponding to a doseresponse study.
Test Substance
BQ-123 was delivered by Clinalfa AB, Darmstadt, Germany in vials containing 5 mg and dissolved and infused intravenously in a 0.9% sodium chloride solution. The doses were 0.1 mg ϭ 0.158 mol/kg (low dose), 0.2 mg ϭ 0.316 mol/kg (medium dose), and 0.3 mg ϭ 0.474 mol/kg (high dose). Infusions were performed by an infusion pump and the duration was 1 h. Placebo was 0.9% sodium chloride solution.
Sample Size
The number of subjects needed in each group was calculated at a significance level of 5% and with a power of 90%. The minimum relevant difference was estimated to be an increase in FE Na of 0.40, and the corresponding SD was estimated to 0.25. The number of subjects was calculated to be 10. We included 13 subjects due to the risk of dropouts.
Enrollment
The study subjects were recruited by announcement and notices in public institutions and private companies.
Ethics
The study was approved by the local Medical Ethics Committee and by the Danish National Board of Health. It was carried out in accordance with the Declaration of Helsinki.
Experimental Procedure
Each subject was instructed to take sodium chloride tablets (2 g) daily for 2 days before each study day. A 24-h urine was collected the day before the study. At 10 PM before the study day a 300-mg lithium carbonate tablet was taken orally. The subjects fasted from midnight, and they were not allowed to smoke on the study day either before or during the examination. On the study day the subjects arrived at the laboratory at 7:30 AM and 200 mL of water was given orally every 30 min from 8 h. The experimental procedure is shown in Fig.1 . Seven clearance periods were performed, each of 30 min duration. Periods 1 to 3 from 9:30 to 11 AM were preinfusion control periods. During periods 4 and 5 BQ-123 or placebo was infused from 11 AM to noon. Periods 6 and 7 were postinfusion control periods from noon to 1 PM. Urine collection, blood sampling, and measurement of blood pressure (BP) and pulse rate are shown in Fig 1. 
Measurements
The GFR and RPF were measured by a constant infusion clearance technique using 51 Cr-EDTA and 125 I-hippuran as reference substances, respectively, as previously described. 8 The PRC was measured by a commercial immunoradiometric assay (Nichols Institute Diagnostics, Geneva, Switzerland). Minimal detection level was 1.4 IU/mL. The coefficients of variation were 2.5% (interassay) and 9.9% (intra-assay).
The Ang II, Aldo, ANP, BNP, and AVP in plasma were determined by radioimmunoassay as previously described. 9 -11 Blood pressure was determined by a UA-743 digital BP meter (A&D Company Ltd., Tokyo, Japan). Serum and I-hippuran, sodium, and lithium; time for blood sampling 2 for determination of vasoactive hormones; and time for measurement of blood pressure (BP) and pulse rate (PR).
urinary concentrations of lithium were measured by atomic absorption spectrophotometry.
Statistics
Statistical analyses were performed using SPSS version 11.5 (SPSS Inc., Chicago, IL). A general linear model with repeated measures was used for comparison of the four dose groups. Parametric tests were used, but if data did not show normality we used nonparametric tests (ie, Friedman's test for paired comparison between several groups and Wilcoxon's signed rank test for paired comparison between two groups). Data are presented as medians with 25 to 75 quartiles or ranges. The significance level was at P Ͻ .05.
Results
Demographics
Thirteen healthy subjects were included in the study. Two were excluded because of an unwillingness to continue and difficulty in emptying the urinary bladder. The remaining 11 subjects fulfilled the study criteria. It comprised 9 men and 2 women, with a median age of 43 years (range 24 to 48 years), and of body mass index of 26.9 (22.9 to 29.2). Table 1 shows that no significant difference existed in clinical and laboratory data immediately before each of the four examinations. Table 2 shows that GFR and RPF were not significantly changed during BQ-123 infusion either during placebo, low, medium, or high doses. No significant differences existed in GFR and RPF either at baseline, during infusion, or postinfusion for GFR or RPF between the four dose regimens. The renovascular resistance (RVR) was significantly changed in the high dose groups (Table 2) . Table 3 shows the effect of BQ-123 infusion on FE Na, C Li , and FE Li .
Glomerular Filtration Rate, Renal Plasma Flow, and Renal Vascular Resistance
Fractional Excretion of Sodium and Lithium
Using a general linear model with repeated measures we found that FE Na. was not significantly changed during infusion of placebo or during low dose BQ-123 infusion, that FE Na was increased during medium dose infusion, and that no significant change was measured during high dose infusion. During infusion of the medium dose of BQ-123 a significant increase in FE Na of 20% was measured in the second infusion period (infusion 30 -60), and FE Na remained significantly elevated in the first postinfusion period (postinfusion 60 -90).
The C Li and FE Li were not significantly changed by BQ-123 infusion at either of the doses used, and no significant difference was found between the dose regimens at any of the time periods. Table 4 shows the effect of BQ-123 on systolic BP, diastolic BP, and pulse rate. Systolic BP was not significantly changed in any of the groups, and no significant difference was measured between the groups for any of the time periods.
BP and Pulse Rate
Diastolic BP was significantly reduced during infusion of BQ-123 both during the first infusion period (infusion 0 to 30) at high dose (placebo: 1.4%, low dose: Ϫ7.4%, Table 1 . Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate (PR), weight, p-creatinine, p-sodium, p-potassium, p-albumin, extracellular volume fraction (EVF), u-sodium, u-potassium in 11 health subjects at the start of each of four examinations using placebo and three different dose of BQ-123 medium dose: Ϫ2.9%, and high dose: Ϫ4.4%, P Ͻ .05), and in the second infusion period (infusion 30 to 60) at both medium and high dose (placebo: 0%, low dose: Ϫ8.8%, medium dose: Ϫ6.3%, P Ͻ .05, and high dose:
Ϫ7.4%, P Ͻ .05). No significant difference was measured between the groups for any of the periods. In the two postinfusion periods diastolic BP remained reduced at low, medium, and high doses of B-123. Pulse rate increased slightly but significantly during infusion of BQ-123 during infusion 0 to 30 at medium dose (placebo: 0%, low dose: 1.9%, medium dose: 7.1%, P Ͻ .05, and high dose: 2%) and infusion 30 to 60 at low, medium, and high doses (placebo: 0%, low dose: 5.5%, P Ͻ .05, medium dose: 7.1%, P Ͻ .05, and high dose: 11%, P Ͻ .05). In the two postinfusion periods pulse rate remained significantly elevated at low, medium, and high doses of BQ-123. Table 5 shows the effect of BQ-123 infusion on PRC, Ang II, and Aldo.
Renin, Angiotensin II, and Aldosterone
The PRC was not significantly changed after placebo either just after infusion (Ϫ15%, P ϭ .196) or at the end of the experiment (Ϫ15%, P ϭ .088). The BQ-123 infusion resulted in a significant increase in PRC at low, medium, and high doses. Just after the infusion and at the end of the experiment the increases were 50% (P ϭ .036) and 58% (P ϭ .009), respectively, in the low dose group. The corresponding values in the medium dose group were 7.8% (P ϭ .003) and 62% (P ϭ .005), and in the high dose group 27% (P ϭ .024) and 60% (P ϭ .008). The baseline levels of PRC were the same at the four examinations (P ϭ .807). Just after the infusion and at the end of the experiment the PRC level deviated significantly between the four examinations (P ϭ .008, and P ϭ .000, respectively). There was a gradual increase in PRC up to the high dose level of BQ-123.
The Ang II was not significantly changed after placebo either just after infusion (25%, P ϭ .159) or at the end of the experiment (13%, P ϭ .336). The BQ-123 infusion resulted in a significant increase in Ang II at low and medium doses, and a borderline significant increase at the high dose. Just after the infusion and at the end of the experiment the increases were 20% (P ϭ .072) and 30% (P ϭ .010), respectively, in the low dose group. The corresponding values in the medium dose group were 40% (P ϭ .120) and 70% (P ϭ .014), and in the high dose group 20% (P ϭ .159) and 50% (P ϭ .358). The baseline levels of Ang II were the same at the four examinations (P ϭ .134). Just after the infusion Ang II was the same at the four examinations (P ϭ .289), but at the end of the experiment there was a borderline significance (P ϭ .064). There was a gradual increase in Ang II up to the medium dose of BQ-123.
The Aldo was not significantly changed by BQ-123 infusion and no significant differences were measured between the dose groups.
Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and Vasopressin Table 5 shows the effect of BQ-123 infusion on ANP, BNP, and AVP.
The ANP was not significantly changed after placebo and the low dose, but ANP was significantly reduced after the medium dose and borderline after the high dose. How- All were studied four times and received infusion with BQ-123 (low dose: 0.1 mg/kg body weight, medium dose: 0.2 mg/kg, and high dose: 0.3 mg/kg), and placebo in a randomized order. Baseline was calculated as the average of four double measurements each of 30 min interval before infusion. During infusion 30 and during infusion 60 corresponds to the average of two double measurements after each of the two infusion periods. Postinfusion 90 and postinfusion 120 corresponds to the average of two double measurements at the end of each of the two control periods after infusion. Medians with ranges in brackets. * P Ͻ .05.
ever, the changes were small, and there was no significant difference between the four dose groups. The BNP and AVP were not significantly changed by BQ-123 infusion and no significant difference was measured between the dose groups.
Discussion
The present study showed that infusion of the endothelin antagonist BQ-123 increased urinary excretion of sodium despite a decrease in diastolic BP, and an increase in renin and angiotensin II in plasma.
In healthy humans infusion of endothelin decreased GFR, RPF and urinary sodium excretion, and increased BP. [12] [13] [14] [15] The effect of endothelin on renal hemodynamics and urinary sodium excretion could be blocked completely or partially by endothelin receptor antagonists. 14, 15 In healthy humans infusion studies with BQ-123 have shown that ET A receptors contribute substantially to the vasoconstriction induced by Ang II in the systemic and renal circulation. 16 In addition, blockade of the ET A receptor with BQ-123 attenuated the systemic and renal hemodynamic effect of inhibition of the nitric oxide synthase. 17, 18 Apparently, the vasoconstrictor effect of ET, the reninangiotensin system, and the sympathetic nervous system is antagonized by nitric oxide-induced vasodilatation in the renal vascular bed. In the present study blockade of the ET A receptor alone with BQ-123 did not change either GFR or RPF during placebo or at the three different doses of BQ-123, and this is in agreement with a previous study.
14 Thus, during baseline conditions ET A does not contribute much to the renal vascular tone. However, BQ-123 has a renal effect because we measured an increase in renal sodium excretion.
We measured a decrease in diastolic BP and an increase in pulse rate after infusion of BQ-123 in low dose, and both during and after infusion at medium and high doses, whereas no effect was seen during placebo treatment. This effect on the systemic circulation is in agreement with many studies of the effect of either parenteral or oral ET A antagonism. 19, 20 In healthy humans local infusion of BQ-123 resulted in vasodilatation of the forearm vascular bed, 1 and reduced peripheral vascular resistance, 6 and .140 .798 .205 .922
All were studied four times and received infusion with BQ-123 (low dose: 0.1 mg/kg body weight, medium dose: 0.2 mg/kg, and high dose: 0.3 mg/kg), and placebo in a randomized order. Blood samples were drawn just before infusion, just after infusion, and 1 hour after the infusion had stopped. Medians with ranges in brackets. * P Ͻ .05.
endogenous ET was suggested to contribute to the regulation of basal vascular tone in healthy humans. In contrast, resting forearm blood flow was not significantly changed in healthy subjects after BQ-123 infusion according to another study, 21 but the infusion time was very short (only a few minutes), and thus much less than in the present and many other studies. Our results show that basal tone in the systemic vascular bed is partially dependent on ET stimulation.
In the present study the total dose of BQ-123 was based on body weight as in some other studies. 16, 18, 22 However, in several studies a fixed dose was used independent of the participants' body weight. 14, 17, [23] [24] [25] [26] The infusion rates of BQ-123 in the present study were in between the low and high infusion rates used by Godard et al, 23, 26 two to six times higher than the doses used by Schmetterer et al 14 and Schmidt et al, 17 corresponding to the three dose levels used in the present dose-response study, and several times higher than the very low infusion rates used by Montanari et al. 16, 18, 22 The total dose of BQ-123 in the present low dose regimen was lower than in some studies, 23, 26 and approximately the same as in another study. 17 However, it was clearly higher than the doses used by Montanari et al. 16, 18, 22 The present study was designed as a doseresponse study to determine the effect of BQ-123. It cannot be excluded that the natriuresis demonstrated in our study could be attributed to a possible displacement of endogenous ET from the ET A receptors allowing an activation of the ET B receptors to produce more nitric oxide and thus reduce renal tubular sodium reabsorption.
We measured an increase in FE Na during BQ-123 infusion in the present study using the medium dose. No effect was seen during placebo and low dose infusion, and during high dose infusion the effect was less pronounced. The changes in FE Na were relatively small. The baseline level at the medium dose was numerically lower, although not statistically significant, than baseline levels at placebo, low, and high doses. However, FE Na also increased at the high dose infusion when the baseline level was numerically higher. A natriuretic effect of BQ-123 has previously been demonstrated in some studies. 26 We measured an unchanged GFR and lithium clearance during BQ-123 infusion. Thus, the natriuresis during infusion cannot be attributed to changes in filtration or the proximal tubular function. It seems most likely that the effect is mediated in the distal part of the nephron. The RVR tended to decrease during BQ-123 infusion, but a significant decrease was only measured during high dose infusion, and the changes were small and might be by chance. A decrease in RVR might be responsible for natriuresis, but a significant increase in FE Na was only measured in the medium dose regimen, during which RVR was unchanged. Both renin and Ang II in plasma were clearly increased during BQ-123 infusion, especially during medium and high doses. Divergent results exist regarding the effect of BQ-123 on renin secretion. [27] [28] [29] Our results show that the natriuretic effect of BQ-123 overrides the sodium retaining effect of increased activity in the renin-angiotensin system. The lesser effect on urinary sodium excretion by the highest dose of BQ-123 most likely can be attributed to a more marked counter-regulatory effect of the renin-angiotensin system or by a more marked decrease in BP at the highest dose.
The BNP and AVP were unchanged, and the changes in ANP were very modest and might be by chance.
The sodium balance influences both the systemic and the hemodynamic response to intervention in the nitric oxide system 8 and thus possibly also the effect of BQ-123. It was not the aim to perform the study either during sodium loading or sodium depletion. However, we intended to avoid sodium depletion by giving sodium chloride tablet (2 g daily) for 2 days before each examination. Urinary sodium excretion did not deviate significantly between the four dose groups and the medians were around 200 to 300 mmol/24 h, indicating that sodium balance for each subject was the same at the four examinations.
In conclusion, our results show that endothelin plays a role during baseline conditions both for systemic vascular tone and the regulation of renal sodium excretion, and that blockade of the ET A receptor apparently can resist and to some extent antagonize the effects of the renin-angiotensin system on BP regulation and sodium balance.
